Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BRAINSTORM CELL THERAPEUTICS INC.BCLI · Entity 7869 | Director · Executive Chairman | July 24, 2026 | July 28, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BRAINSTORM CELL THERAPEUTICS INC.
Report date July 24, 2026 · Filed July 28, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.00 · Expires 2036-07-24 | Direct | 900,000 |
Reported balance
After 2026-07-24 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-07-24 · Grant · Acquired 900,000 · Balance 900,000 F1: Represents options to purchase common stock, granted under the Issuer's 2014 Stock Incentive Plan. F2: The stock options vest over 48 months, with 25% vesting on July 24, 2027 and 1/48th vesting monthly thereafter, provided that the Reporting Person remains employed by the Issuer through each applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents options to purchase common stock, granted under the Issuer's 2014 Stock Incentive Plan.
F2: The stock options vest over 48 months, with 25% vesting on July 24, 2027 and 1/48th vesting monthly thereafter, provided that the Reporting Person remains employed by the Issuer through each applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 24, 2026 Filed Jul 28, 2026 21:00 UTC | BRAINSTORM CELL THERAPEUTICS INC. BCLI · Entity 7869 | GrantStock Option (Right to Buy) · Derivative | 900,000 | $0.00 Strike: $1.00 | $0.00 |
DisclosureSEC source: 0001104659-26-087584 · tm2621485-1_4seq1.xml · derivative · entry 1 Pitts Peter Joe · CIK 0002138486 · Director · Executive Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 900,000 Underlying: Common Stock · 900,000 shares Expires 2036-07-24 F1 · security: Represents options to purchase common stock, granted under the Issuer's 2014 Stock Incentive Plan. F2 · derivative.exercise_date: The stock options vest over 48 months, with 25% vesting on July 24, 2027 and 1/48th vesting monthly thereafter, provided that the Reporting Person remains employed by the Issuer through each applicable vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.